Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

Bristol-Myers’ Schizophrenia Drug Falls Short in Key Trial

Daniel Kim Views  

Shutterstock
Shutterstock

Bristol-Myers Squibb (BMS) recently revealed that a late-stage clinical trial for the expanded use of its medication, Cobenfy, did not yield statistically significant results.

According to reports, the medication, which was approved last year, failed to meet its primary objective in this trial involving schizophrenia patients who did not improve with current antipsychotic therapies.

At week six of the trial, the medication demonstrated a 2 percentage point drop in a symptom severity measure compared to a placebo.

Bristol-Myers has completed the analysis of all trial data and intends to present the findings in depth at a future academic conference.

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[LIFESTYLE] Latest Stories

  • Too Much Sitting May Raise Risk of Alzheimer’s, Even If You Exercise, Study Finds
  • Got a Family History of Rare Dementia? This Gene Might Protect You
  • Experts Say Tea, Apples, and Cocoa Might Be the Secret to Lower BP
  • Living Near a Golf Course? Your Risk for Parkinson’s Might Be Higher
  • Prunes: The Underrated Superfruit Your Cardiologist Might Approve Of
  • 3 Daily Habits That Might Be Aging Your Brain Faster Than You Think